Quintiles

WCG’s MedAvante-ProPhase expands executives

Tuesday, August 15, 2017

WIRB-Copernicus Group (WCG), a provider of solutions that measurably improve the quality and efficiency of clinical research, announced that industry experts Steven Herne and Michael Cioffi have joined the leadership of MedAvanteProPhase, the Group’s electronic clinical outcomes assessment (eCOA) arm. Herne and Cioffi are tasked with expanding MedAvante-ProPhase’s already formidable portfolio of services and technologies, which improve the quality of clinical trial data collection and analysis in the fields of CNS and mental health.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

Ergomed appoints Dr Dan Weng as CEO

Friday, June 23, 2017

Ergomed, a company dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs, announced the strengthening of its executive team with the appointment of Dr. Dan Weng as its new chief executive officer and a board director of Ergomed. Dr. Weng joins Ergomed with effect from 1 July 2017 from EPS Holdings (EPSHD), a global CRO listed on the Tokyo Stock Exchange.

[Read More]

Bridging the gap: Incorporating research into care

Monday, April 10, 2017

A few years ago, the idea that primary care physicians might offer clinical trials as a routine part of care seemed far-fetched. But today, a growing body of evidence supports the notion that integrating research into clinical care can improve efficiencies, bolster patient engagement and reduce cost.

[Read More]

INC Research adds James Featherstone, Janet Baldwin, Nathalie Doize & Alastair MacDonald to team

Friday, March 31, 2017

INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC’s continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.

[Read More]